PTAB invalidates Sanofi injector patent

Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Sanofi and C4X in $493m licensing deal

13 April 2021 UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.

Americas

French healthcare company makes $1.2bn AI drug discovery deal

18 August 2022 Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.

More on this story

Americas

French healthcare company makes $1.2bn AI drug discovery deal

18 August 2022 Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.

Big Pharma

Sanofi and C4X in $493m licensing deal

More on this story

Americas

French healthcare company makes $1.2bn AI drug discovery deal

18 August 2022 Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.

Big Pharma

Sanofi and C4X in $493m licensing deal